Viral neuroinvasion as a marker for BBB integrity following exposure to cholinesterase inhibitors

• Published in: Life sciences (1973) Vol. 68; no. 9; pp. 985 - 990
• Main Authors: Grauer, E., Nathan, D.Ben, Lustig, S., Kobiler, D., Kapon, J., Danenberg, H.D.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 19.01.2001
• Subjects: Alphavirus Infections - blood; Alphavirus Infections - virology; Animals; Blood-brain barrier; Blood-Brain Barrier - drug effects; Blood-Brain Barrier - physiology; Brain - virology; Central Nervous System Diseases - virology; Cholinesterase inhibitors; Cholinesterase Inhibitors - toxicity; Dose-Response Relationship, Drug; Female; Lethal Dose 50; Mice; Mice, Inbred ICR; Permeability - drug effects; Physostigmine; Physostigmine - toxicity; Pyridostigmine; Pyridostigmine Bromide - toxicity; Sindbis Virus; Soman; Soman - toxicity; Viremia - blood; Viremia - virology; Physostigmine; Pyridostigmine; Soman; Blood-brain barrier; Cholinesterase inhibitors; Sindbis virus
• ISSN: 0024-3205; 1879-0631
• DOI: 10.1016/S0024-3205(00)01000-6

Exposure to the nerve agent soman, an irreversible cholinesterase (ChE) inhibitor, results in changes in blood-brain barrier permeability attributed to its seizure-induced activity. However, smaller BBB changes may be independent of convulsions. Such minor injury may escape detection. A nonneuroinvasive neurovirulent Sindbis virus strain (SVN) was used as a marker for BBB permeability. Peripheral inoculation of mice with 2×10 3 plaque forming units (PFU) caused up to 10 5 PFU/ml viremia after 24 hours with no signs of central nervous system (CNS) infection and with no virus detected in brain tissue. Intra-cerebral injection of as low as 1–5 PFU of the same virus caused CNS infection, exhibited 5–7 days later as hind limb paralysis and death. Soman (0.1–0.7 of the LD 50,) was administered at peak viremia (1 day following peripheral inoculation). Sublethal soman exposure at as low as 0.1LD 50 resulted in CNS infection 6–8 days following inoculation in 30–40% of the mice. High virus titer were recorded in brain tissue of sick mice while no virus was detected in healthy mice subjected to the same treatment. No changes in the level of viremia or changes in viral traits were observed in the infected mice. The reversible anticholinesterases physostigmine (0.2 mg/kg, s.c.) and pyridostigmine (0.4 mg/kg, i.m.) injected at a dose equal to 0.1LD 50 induced similar results. Thus, both central and peripheral anticholinesterases (anti-ChEs) induce changes in BBB permeability sufficient to allow, at least in some of the mice, the invasion of this otherwise noninvasive but highly neurovirulent virus. This BBB change is probably due to the presence of cholinesterases in the capillary wall. SVN brain invasion served here as a highly sensitive and reliable marker for BBB integrity.